RNA
Atrium Therapeutics, Inc.
Biotechnology
Market Cap$218M
5Y Perf.-54.9%
Build Your Comparison
Side-by-side financial analysisRNA
RARE
Try popular comparisons:
Stock Comparison
RNA vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.-67.6%
RNA vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  RNA |  RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $218M | $2.50B |
| Revenue (TTM) | $37M | $669M |
| Net Income (TTM) | $-396M | $-609M |
| Gross Margin | -275.6% | 83.6% |
| Operating Margin | -11.6% | -83.9% |
| Total Debt | $4M | $1.28B |
| Cash & Equiv. | $270M | $434M |
RNA vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RNA
RARE
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Atrium Therapeutics… (RNA) | 100 | 45.1 | -54.9% |
| Ultragenyx Pharmace… (RARE) | 100 | 32.4 | -67.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RNA vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RARE leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Atrium Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇RARE emerged as the overall leader. Track its performance:
RNA
Atrium Therapeutics, Inc.
The Income Pick
RNA is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.38
- Rev growth 70.9%, EPS growth -55.0%, 3Y rev CAGR 26.4%
- -55.3% 10Y total return vs RARE's -59.5%
Best for: income & stability and growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Quality Compounder
RARE carries the broadest edge in this set and is the clearest fit for quality and momentum.
- -91.0% margin vs RNA's -10.8%
- -31.6% vs RNA's -57.2%
- -45.8% ROA vs RNA's -71.5%, ROIC -89.4% vs -10.0%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  RNA | 70.9% revenue growth vs RARE's 20.1% |
| Quality / Margins |  RARE | -91.0% margin vs RNA's -10.8% |
| Stability / Safety | RNA | Beta 1.38 vs RARE's 1.43 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RARE | -31.6% vs RNA's -57.2% |
| Efficiency (ROA) | RARE | -45.8% ROA vs RNA's -71.5%, ROIC -89.4% vs -10.0% |
RNA vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
RNA vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRNALAGGINGRARE
RAREUltragenyx Pharmaceut…
2leads
RNAAtrium Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RARE4/6
Valuation MetricsMultiples, price ratios, and targets
RARE2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RNA5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
RNA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RARE leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $669M annually — 18.2x RNA's $37M. Profitability is closely matched — net margins range from -91.0% (RARE) to -10.8% (RNA). On growth, RNA holds the edge at +11.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RNAAtrium Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $37M | $669M |
| EBITDAEarnings before interest/tax | -$423M | -$536M |
| Net IncomeAfter-tax profit | -$396M | -$609M |
| Free Cash FlowCash after capex | -$416M | -$487M |
| Gross MarginGross profit ÷ Revenue | -2.8% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -11.6% | -83.9% |
| Net MarginNet income ÷ Revenue | -10.8% | -91.0% |
| FCF MarginFCF ÷ Revenue | -11.3% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.5% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -7.8% | -17.2% |
RARE leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
RARE leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | RNAAtrium Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $218M | $2.5B |
| Enterprise ValueMkt cap + debt − cash | -$48M | $3.3B |
| Trailing P/EPrice ÷ TTM EPS | -2.85x | -4.35x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 11.71x | 3.71x |
| Price / BookPrice ÷ Book value/share | 1.05x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RARE leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
RNA leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
RNA delivers a -85.9% return on equity — every $100 of shareholder capital generates $-86 in annual profit, vs $-6 for RARE.
| Metric | RNAAtrium Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -85.9% | -6.1% |
| ROA (TTM)Return on assets | -71.5% | -45.8% |
| ROICReturn on invested capital | -10.0% | -89.4% |
| ROCEReturn on capital employed | -9.0% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$266M | $842M |
| Cash & Equiv.Liquid assets | $270M | $434M |
| Total DebtShort + long-term debt | $4M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x |
RNA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
RNA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RNA five years ago would be worth $4,846 today (with dividends reinvested), compared to $2,537 for RARE. Over the past 12 months, RARE leads with a -31.6% total return vs RNA's -57.2%. The 3-year compound annual growth rate (CAGR) favors RNA at 0.7% vs RARE's -19.6% — a key indicator of consistent wealth creation.
| Metric | RNAAtrium Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -82.3% | +7.5% |
| 1-Year ReturnPast 12 months | -57.2% | -31.6% |
| 3-Year ReturnCumulative with dividends | +2.2% | -48.1% |
| 5-Year ReturnCumulative with dividends | -51.5% | -74.6% |
| 10-Year ReturnCumulative with dividends | -55.3% | -59.5% |
| CAGR (3Y)Annualised 3-year return | +0.7% | -19.6% |
RNA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RNA and RARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
RNA is the less volatile stock with a 1.38 beta — it tends to amplify market swings less than RARE's 1.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RARE currently trades 59.9% from its 52-week high vs RNA's 17.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RNAAtrium Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 1.43x |
| 52-Week HighHighest price in past year | $73.06 | $42.37 |
| 52-Week LowLowest price in past year | $11.40 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +17.5% | +59.9% |
| RSI (14)Momentum oscillator 0–100 | 43.3 | 55.1 |
| Avg Volume (50D)Average daily shares traded | 245K | 1.5M |
Evenly matched — RNA and RARE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RNA as "Hold" and RARE as "Buy". Consensus price targets imply 96.1% upside for RNA (target: $25) vs 90.5% for RARE (target: $48).
| Metric | RNAAtrium Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $25.00 | $48.36 |
| # AnalystsCovering analysts | 16 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RARE leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). RNA leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallAtrium Therapeutics, Inc. (RNA)Leads 2 of 6 categories
Loading custom metrics...
RNA vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RNA or RARE a better buy right now?
For growth investors, Atrium Therapeutics, Inc.
(RNA) is the stronger pick with 70. 9% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RNA or RARE?
Over the past 5 years, Atrium Therapeutics, Inc.
(RNA) delivered a total return of -51. 5%, compared to -74. 6% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: RNA returned -55. 3% versus RARE's -59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RNA or RARE?
By beta (market sensitivity over 5 years), Atrium Therapeutics, Inc.
(RNA) is the lower-risk stock at 1. 38β versus Ultragenyx Pharmaceutical Inc. 's 1. 43β — meaning RARE is approximately 4% more volatile than RNA relative to the S&P 500.
04Which is growing faster — RNA or RARE?
By revenue growth (latest reported year), Atrium Therapeutics, Inc.
(RNA) is pulling ahead at 70. 9% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc. grew EPS 7. 3% year-over-year, compared to -55. 0% for Atrium Therapeutics, Inc.. Over a 3-year CAGR, RNA leads at 26. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RNA or RARE?
Ultragenyx Pharmaceutical Inc.
(RARE) is the more profitable company, earning -85. 4% net margin versus -411. 9% for Atrium Therapeutics, Inc. — meaning it keeps -85. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RARE leads at -79. 5% versus -412. 6% for RNA. At the gross margin level — before operating expenses — RNA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RNA or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RNA or RARE better for a retirement portfolio?
For long-horizon retirement investors, Atrium Therapeutics, Inc.
(RNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (RNA: -55. 3%, RARE: -59. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RNA and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.